Bank of New York Mellon Corp grew its position in shares of Patheon NV (NASDAQ:PTHN) by 9.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 98,992 shares of the company’s stock after acquiring an additional 8,912 shares during the quarter. Bank of New York Mellon Corp owned 0.07% of Patheon NV worth $3,453,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. OppenheimerFunds Inc. acquired a new position in Patheon NV during the 1st quarter worth approximately $24,290,000. Redmile Group LLC boosted its position in Patheon NV by 87.6% during the 1st quarter. Redmile Group LLC now owns 826,843 shares of the company’s stock worth $21,779,000 after acquiring an additional 386,123 shares during the last quarter. Chicago Capital Management LLC acquired a new position in Patheon NV during the 2nd quarter worth approximately $20,939,000. Citadel Advisors LLC boosted its position in Patheon NV by 20.8% during the 1st quarter. Citadel Advisors LLC now owns 434,403 shares of the company’s stock worth $11,442,000 after acquiring an additional 74,912 shares during the last quarter. Finally, ARP Americas LLC acquired a new position in Patheon NV during the 2nd quarter worth approximately $14,992,000.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/09/bank-of-new-york-mellon-corp-purchases-8912-shares-of-patheon-nv-pthn.html.

A number of research firms have weighed in on PTHN. BidaskClub downgraded Patheon NV from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 2nd. Jefferies Group LLC reissued a “hold” rating and issued a $35.00 price objective on shares of Patheon NV in a report on Friday, July 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. Patheon NV presently has a consensus rating of “Hold” and a consensus target price of $33.60.

Shares of Patheon NV (NASDAQ:PTHN) opened at 34.98 on Monday. Patheon NV has a 12-month low of $24.45 and a 12-month high of $35.02. The firm has a market cap of $5.08 billion and a P/E ratio of 44.85. The stock has a 50 day moving average price of $34.98 and a 200 day moving average price of $34.98.

About Patheon NV

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.

Want to see what other hedge funds are holding PTHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Patheon NV (NASDAQ:PTHN).

Institutional Ownership by Quarter for Patheon NV (NASDAQ:PTHN)

Receive News & Stock Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related stocks with our FREE daily email newsletter.